Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.7K
2.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

1.8K
Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.

Cancer discovery·2021
Same author

Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.

Blood advances·2021
Same author

Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.

NPJ precision oncology·2021
Same author

Overview of the TREC 2019 Precision Medicine Track.

The ... text REtrieval conference : TREC. Text REtrieval Conference·2021
Same author

Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.

Cancer medicine·2021
Same author

Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.

European urology oncology·2021

Related Experiment Video

Updated: May 6, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.0K

CanDrA: cancer-specific driver missense mutation annotation with optimized features.

Yong Mao1, Han Chen, Han Liang

  • 1Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.

Plos One
|November 9, 2013
PubMed
Summary
This summary is machine-generated.

Identifying cancer driver mutations is crucial for targeted therapies. The new CanDrA tool accurately predicts missense driver mutations using machine learning, outperforming existing methods in cancer genomics.

More Related Videos

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.0K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K

Related Experiment Videos

Last Updated: May 6, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.0K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.0K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K

Area of Science:

  • Genomics
  • Computational Biology
  • Cancer Research

Background:

  • Distinguishing driver mutations from passenger mutations is essential for understanding oncogenesis.
  • Missense mutations are frequent and potential drivers, but identifying them is challenging due to their low prevalence and complex functions.
  • Existing methods for predicting driver mutations are limited, necessitating improved computational approaches.

Purpose of the Study:

  • To develop and validate a machine learning-based tool, CanDrA, for accurate prediction of missense driver mutations.
  • To enhance the identification of functionally significant mutations in cancer genomes.
  • To provide a robust tool for cancer driver annotation.

Main Methods:

  • Developed CanDrA using a comprehensive set of 95 structural and evolutionary features.
  • Integrated predictions from over 10 functional prediction algorithms (e.g., CHASM, SIFT, MutationAssessor).
  • Employed feature optimization and supervised training on cancer datasets.

Main Results:

  • CanDrA demonstrates superior performance in predicting missense driver mutations compared to existing tools.
  • The tool was validated using glioblastoma multiforme and ovarian carcinoma datasets from The Cancer Genome Atlas and Cancer Cell Line Encyclopedia.
  • Feature optimization and machine learning significantly improved driver mutation prediction accuracy.

Conclusions:

  • CanDrA is a powerful new tool for identifying missense driver mutations in cancer.
  • The approach advances computational methods for cancer genomics and personalized medicine.
  • Accurate driver mutation identification facilitates the development of targeted cancer therapies.